SYNLOGIC, INC. Deferred Offering Costs
SYNLOGIC, INC. (SYBX) had Deferred Offering Costs of $1.66 million as of 2015-09-30, per its 10-Q filed 2015-11-13.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2016-03-30
- 2015-09-30: Deferred Offering Costs $1.66M.
- 2014-12-31: Deferred Offering Costs $92.00K.
| Period end | Deferred Offering Costs |
|---|---|
| 2015-09-30 | $1.66M 10-Q · filed 2015-11-13 |
| 2014-12-31 | $92.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |